Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT-PET as a Biomarker for Pemetrexed Response in NSCLC
NCT02274038Terminated
- Sponsor
- University of Pennsylvania
- Start
- Mar 2015
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Open-label trial of fluorothymidine F-18 in non-small cell lung cancer (NSCLC), sponsored by University of Pennsylvania. Primary endpoints: Baseline 18F-thymidine PET/CT and Post-therapy 18F-thymidine PET/CT to Assess Flare Response at 24 hours. Started Mar 2015; status: terminated.
02
Drugs
fluorothymidine F-18
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02274038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274038.